We report a comprehensive examination of rat hepatic CYP1A2 and CYP2E1 ontogeny. We
compare the data to human data to determine the rat's capacity as a model to identify CYP …

This review focuses on one of the key factors accounting for differences in drug/metabolite
exposure in paediatric and elderly subjects compared with that of the adult population, that …

Animal models are commonly used in the preclinical development of new drugs to predict
the metabolic behaviour of new compounds in humans. It is, however, important to realise …

Polymorphisms in drug-metabolizing enzymes and drug transporters contribute to wide and
inheritable variability in drug pharmacokinetics, response and toxicity. One of the less well …

Children's risks from environmental toxicant exposure can be affected by pharmacokinetic
factors that affect the internal dose of parent chemical or active metabolite. There are …

Pharmacogenetics is the study of how interindividual variations in the DNA sequence of
specific genes affect drug response. This article highlights current pharmacogenetic …

The pharmaceutical industry continues to look for ways to reduce drug candidate attrition
throughout the drug discovery and development process. A significant cause of attrition is …

Cytochrome P450 3A subfamily members (CYP3A) are the most abundant liver cytochrome
P450 forms, responsible for the biotransformation of over 50% of all drugs. The expression …

Drug metabolism importantly determines drug concentrations. The efficacy and safety of
many drugs prescribed for children are, therefore, dependent on intraindividual and …

Solithromycin is a novel fluoroketolide antibiotic that is both a substrate and time-dependent
inhibitor of CYP3A. Solithromycin has demonstrated efficacy in adults with community …